Business Wire

ZTE Introduces Spro Plus Smart Projector

Del

ZTE Mobile Devices today unveiled the Spro Plus portable smart projector, following the acclaimed Spro 2. Spro Plus is a new category of the Spro family, and ZTE aims to provide a high level of entertainment and business opportunities for users. Spro Plus helps business associates and friends meet anywhere at any time, with its leading voice conference, projection, touch-screen and innovative visual design features. The external USB camera also allows for multi-party video communication via applications like Skype.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160221005021/en/

Spro Plus (Photo: Business Wire)

Spro Plus (Photo: Business Wire)

“The Spro Plus is ZTE Mobile Devices’ latest example of igniting digital life with imagination,” said Adam Zeng, CEO, ZTE Mobile Devices. “We’re proud of the Spro Plus, which showcases a pioneering technology as a first-rate product and delivers an even more intuitive user experience. This allows our users to have unlimited business and entertainment opportunities.”

One of the Spro Plus’ highlights is a larger, 8.4-inch Android™ AMOLED touch-screen with 2K resolution, paired with a 12100mAH battery for an enhanced user experience. The Spro Plus will be available in both a Wi-Fi-only version as well as a Wi-Fi and 4G LTE version.

Spro Plus helps users work smart and play hard. Its leading visual capabilities include its vertical and horizontal keystone correction, which is its ability to project onto any place in any direction without distorting the image. Its autofocus keeps the image sharp and clear. This is all achieved by its stylish, circular design. It uniquely uses laser instead of LED technology to project at 500lm, the ideal luminescence for either broad daylight or dark rooms, ensuring the best visual experience for users. This generation of Spro comes with an improved projection ratio. Placing the Spro Plus 2.4 meters away from any surface will project an image up to 80 inches across.

When it comes to great audio, the Spro Plus features a JBL Audio System, which includes high quality audio outputs via two 4w speakers and a crystal clear voice pickup via high performance HARMAN sub-miniature microphones. Its ability to detect voices more than five meters from Spro Plus makes it easy to conduct group meetings in any location.

Michael Mauser, President of HARMAN’s Lifestyle Division, said, “We’re very excited to be partnering with ZTE on the Spro Plus. Our engineers have done an outstanding job of developing the JBL Audio system to make the Spro Plus truly amazing. We expect the Spro Plus to be a very strong performer in the marketplace.”

Spro Plus follows the Spro 1 and 2, which sold over 500,000 units worldwide and is currently nominated for GSMA's 2016 Glomo Awards in the ‘Best Connected Consumer Electronic Device’ category. The original ZTE Spro won in the same category in 2015.

ZTE Mobile Devices showcased Spro Plus at Mobile World Congress in Barcelona today. It will be available globally by summer 2016.

More information can be found at http://www.ztedevice.com/specialtopics/mwc_2016/.

   

Spro Plus Specifications

 
Optical Specs: 500lm WXGA DLP

Keystone (Horizontal + Vertical)

1.4:1 (80”@2.4m)

 
OS, Platform & Functions: Android M

SnapDragon 801\ 625

VoLTE HD Voice (LTE Version)

Network Support: Full Band LTE (LTE Version)
Connectivity: WIFI b/g/n/ac (2.4GHz & 5GHz)

BT 4.1

 
Display, Acoustic & Size

8.4 2560*1600 AMOLED LCD

2*4W Harman Sound with Dolby

5m+ Voice Pickup

228.8*150*24.8mm

 
Memory 3GB RAM+32/128GB ROM

SDXC up to 2TB

Power Supply 12100mAh above

Charger 19V/3.4A

Optional Accessories

Game Controller

Bag

Tripod

USB Camera

Bluetooth Speaker Box

 

About ZTE Mobile Devices

ZTE Mobile Devices is a division of ZTE Corporation, a global telecommunications equipment, networks and mobile devices company headquartered in Shenzhen, China. ZTE is a publicly traded company listed on the Hong Kong and Shenzhen stock exchanges.

ZTE is one of the global leaders in the mobile handset manufacturing industry in the world, offering a complete range of mobile devices, including mobile phones, tablets, mobile broadband modems and hotspots and family desktop integration terminals. For more information, please visit: www.ztedevice.com

Contact information

ZTE Corporation
Eva Chen, +86 21 68896271
chen.zhengying@zte.com.cn
or
WE China
+86 10 59001278
ztechina@we-worldwide.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom